Our team and partners

Meet our team of energetic, experienced and curious people.

Our Executive Management

Remko van Leeuwen, CEO

Key Facts
• Scientific and industrial background in infectious diseases
• Extensive experience in clinical trial management
• Great network infectious diseases field

Read more >
Leonie de Best, CBO

Key facts
• Renowned background in pharmaceutical product development (CMC).
• Extensive management experience in the successful development of biotech companies and their products

Read more >

Our Advisors


Our investors

Oost NL

SurvivX is currently supported by “Vroege Fase Financiering” from Oost NL (East Netherlands Development Agency), an agency that focusses its activities and projects on strengthening and stimulating the economy of the provinces of Gelderland and Overijssel, the Netherlands. Oost NL plays an important role in executing the economic policies of the Dutch government and the Provinces of Gelderland and Overijssel and its various city governments. To achieve this it is necessary to encourage a close cooperation between businesses, regional institutes, knowledge institutes, and intermediaries. Oost NL acts as a bridge between government, companies and knowledge institutes.

Our partners


INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. INCATE does so by providing advice, community and funding. Our focus is on the development of new therapies, diagnostics and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR). SurvivX has recently been awarded a INCATE resident status.


The Centre for Cellular and Molecular Platforms (C-CAMP) is an initiative that is supported by Department of Biotechnology from the Government of India. They are a catalyst of cutting-edge research and innovation in the life sciences, and facilitate Bioscience Research and Entrepreneurship by providing Research, Development, Training and Services in state-of-the-art Technology Platforms. C-CAMP is of our key corporation partner in India for the development of SUR-101.

Institute of Life Sciences India

The core-technology from SurvivX, SUR-101 is the results of years of dedicated by years of studies by Professor Balachandran Ravindran from the Institute for Life Sciences (ILS) in India. The research activity of ILS focuses on basic, applied, translational and interdisciplinary focus areas, and are by 26 faculties and are supported by 150 research fellows, 25 post-doctoral fellows, and women scientists, as well as more than 100 project staff. Like C-CAMP, the administrative control of the institute is with the Department of Biotechnology from the Government of India.

Amsterdam UMC

We collaborate with by the 2 leading centers in sepsis research in the Netherlands. At Amsterdam UMC we collaborate with professor Tom van der Poll. The research headed by Tom van der Poll focuses on the immunology and immunotherapy of sepsis and has a strong translational character.

Radboud UMC

The premises of SurvivX are located on the campus of Radboud UMC in Nijmegen in the Eastern part of the Netherlands. Here we collaborate with professor Mihai Netea who is head of the Department of Experimental Medicine and specialized in infectious disease, immunology, and global health. Moreover, we work with professor Peter Pickkers at the department of Intensive Care of Radboud UMC. His research focuses on pharmacological modulation of the innate immune response in translational models and patients.

Leonie de Best has a background in Analytical Chemistry and has over 20 years of extensive management experience in biotech/life science industry, of which 10 years at senior executive level (COO/CBO).

Leonie has a broad experience in the management of business processes in the field of (in-vitro) diagnostic assay and pharmaceutical product development from research stage until European and US market registrations.

With this experience she supports life science organizations like Madam Therapeutic to efficiently achieve their ambitious goals, bringing valuable and high quality health care products and services to patients.

Remko van Leeuwen has more than 35 years of R&I experience under his belt, both in the industry as well as in the academic arena. He has a medical background, and been trained as a clinical epidemiologist and has extensive experienced in clinical infectious disease management. From 2011-2023 he acted as founder and CEO of Madam Therapeutics, a Dutch Life Sciences company that is developing antibiotics with new mechanism of action to overcome the problem of antimicrobial resistance. Furthermore, he acts as vice chair of the BEAM Alliance (the association of biotech companies in Europe combating antimicrobial resistance, and is board member of AMR-Global, a Dutch public private partnership to tackle the problem of antimicrobial resistance in low- and middle-income countries via a multisectoral approach (human and veterinary health, environment, water and agriculture). He is also working as strategic advisor and senior staff member at Aidsfonds, the Netherlands, coordinating programs to find a cure for HIV.